Cremagnani L, Cantalamessa L, Orsatti A, Vigna L, Vallino F, Buccianti G
Institute of Internal Medicine, Immunopathology and Infectious Diseases, University of Milan, Italy.
Clin Nephrol. 1993 May;39(5):282-6.
On the basis of previously described effects of recombinant human erythropoietin (rhEPO) treatment on endocrine abnormalities present in uremia, we assessed the possible effect of treatment with rhEPO on growth hormone (GH) response to growth hormone releasing hormone (GHRH) in a group of uremic patients. Eight patients on maintenance hemodialysis for 12 to 228 months, not previously treated with rhEPO, were tested with 100 micrograms of GHRH i.v. in bolus before and after three months of rhEPO treatment (40 U/kg i.v. three times a week). Before treatment, the GH response to GHRH was characterized, in uremic patients, by remarkable differences in plasma GH values and in the pattern of response curve in single patients. The variability of GH response was not modified after rhEPO treatment; however, an overall potentiation of GH response with a significant increase of plasma GH (p = 0.017 at 15 min, p = 0.035 at 30 min after GHRH injection) was observed in the tests performed after treatment. rhEPO administration induced an evident improvement of anemia, blood hemoglobin concentration being 5.3-7.6 g/dl before and 9.1-11.3 g/dl after treatment; however a demonstrable correlation between the potentiation of GH response to GHRH and the increase of hemoglobin concentration was not observed.
基于先前描述的重组人促红细胞生成素（rhEPO）治疗对尿毒症患者内分泌异常的影响，我们评估了rhEPO治疗对一组尿毒症患者生长激素（GH）对生长激素释放激素（GHRH）反应的可能影响。8名维持性血液透析12至228个月、此前未接受rhEPO治疗的患者，在rhEPO治疗3个月（静脉注射40 U/kg，每周3次）前后，分别静脉推注100微克GHRH进行测试。治疗前，尿毒症患者对GHRH的GH反应表现为血浆GH值及单例患者反应曲线模式存在显著差异。rhEPO治疗后GH反应的变异性未改变；然而，在治疗后进行的测试中，观察到GH反应总体增强，注射GHRH后15分钟时血浆GH显著升高（p = 0.017），30分钟时（p = 0.035）。rhEPO给药使贫血明显改善，治疗前血血红蛋白浓度为5.3 - 7.6 g/dl，治疗后为9.1 - 11.3 g/dl；然而，未观察到GH对GHRH反应增强与血红蛋白浓度升高之间存在明显相关性。
